AbbVie completed the acquisition of ImmunoGen for $10.1bn.

AbbVie, a pharmaceutical company, completed the acquisition of ImmunoGen, a biotechnology company focused on the development of antibody-drug conjugate therapeutics for the treatment of cancer, for $10.1bn. "The acquisition of ImmunoGen demonstrates our commitment to deliver on our long-term growth strategy and enables AbbVie to further diversify our oncology pipeline across solid tumors and hematologic malignancies. Together, AbbVie and ImmunoGen have the potential to transform the standard of care for people living with cancer," Richard A. Gonzalez, AbbVie Chairman and CEO.